410071-23-7

Upstream product

• 109-99-9 tetrahydrofuran 
• 1135-24-6 (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid 
• 110-52-1 1,4-dibromo-butane 

Downstream Products

• 475561-36-5 (E)-4-(nitrooxy)butyl 3-(4-hydroxy-3-methoxyphenyl)acrylate 
• 1330531-03-7 (±)-(E)-2-methoxy-4-(3-(4-(nitrooxy)butoxy)-3-oxoprop-1-en-1-yl)phenyl 2-(1-(2-chloroacetoxy)pentyl)benzoate 
• 1330531-09-3 (+/-)-(E)-2-[2-(morpholinoacetoxy)pentyl]benzoic acid {2-methoxy-4-[2-(4-nitrooxybutoxycarbonyl)vinyl]}phenyl ester hydrochloride 
• 1330531-12-8 (+/-)-(E)-2-[2-(diethylaminoacetoxy)pentyl]benzoic acid {2-methoxy-4-[2-(4-nitrooxybutoxycarbonyl)vinyl]}phenyl ester hydrochloride 
• 1613704-90-7 4-((E)-3-(4-bromobutoxy)-3-oxoprop-1-enyl)-2-methoxyphenyl-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoate 
• 1613704-74-7 2-methoxy-4-((E)-3-oxo-3-(4-(piperidin-1-yl)butoxy)prop-1-en-1-yl)phenyl-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)benzoate 
• 1613704-75-8 2-methoxy-4-((E)-3-(4-morpholinobutoxy)-3-oxoprop-1-enyl)-phenyl-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoate 
• 1613704-76-9 2-methoxy-4-((E)-3-(4-(4-methylpiperazin-1-yl)butoxy)-3-oxoprop-1-enyl)phenyl-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoate 
• 1613704-78-1 tert-butyl 4-(4-((E)-3-(3-methoxy-4-(2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoyloxy)phenyl)acryloyloxy)butyl)piperazine-1-carboxylate 
• 1613704-60-1 C₁₉H₂₇NO₄ 
• 1613704-61-2 C₁₈H₂₅NO₅ 
• 1613704-62-3 C₁₉H₂₈N₂O₄ 
• 1613704-63-4 C₂₄H₃₀N₂O₄ 
• 1613704-64-5 C₂₃H₃₄N₂O₆ 

Relevant academic research and scientific papers

Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance

Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM.

benzyl ethylene acrylic farnesyl thiophosphoro salicylic acid derivatives and its preparation and use

The invention discloses a phenyl acrylic acid farnesyl thiosalicylic acid (FTA) derivative as well as a preparation method and an application. The phenyl acrylic acid farnesyl thiosalicylic acid derivative is a compound of a formula (I) in the specification, wherein X1 represents O or NH; X2 represents O or NH; n is equal to 1- 3; R represents H or OCH3. By coupling ferulic acid and p-hydroxy cinnamic acid fragments with carboxyl of FTA, the capability of a target molecule in scavenging free radicals is improved, the anti-tumor effect of the molecule is improved, and then a compound with anti-tumor activity or anti-inflammatory activity higher than those of FTA is obtained.

Discovery of a ring-opened derivative of 3-n-butylphthalide bearing NO/H2S-donating moieties as a potential anti-ischemic stroke agent

To search for novel anti-ischemic stroke agents with higher potency than a known drug 3-n-butylphthalide (NBP), a series of ring-opened derivatives of NBP bearing both nitric oxide (NO) and hydrogen sulfide (H2S)-donating moieties (NO/H2S-NBP) (8a-8o) were designed, synthesized, and biologically evaluated. The most active compound 8d was more potent than NBP and the corresponding H2S-NBP 10 or NO-NBP 13 in inhibition of the ADP-induced platelet aggregation in vitro. In addition, 8d produced moderate levels of NO and H2S, which could be beneficial for improving cardiovascular and cerebral circulation. More importantly, in a rat model of transient focal cerebral ischemia, oral treatment with 8d improved neurobehavioral function, reduced the infarct brain size and brain-water content, and enhanced the levels of brain antioxidant SOD, GSH and GSH-Px but diminished the level of oxidant MDA. These protective effects of 8d against the ischemia/reperfusion (I/R)-related brain damage were greater than that of NBP, suggesting that 8d may be a promising agent for further investigation.

Synthesis and biological evaluation of hybrids from farnesylthiosalicylic acid and hydroxylcinnamic acid with dual inhibitory activities of Ras-related signaling and phosphorylated NF-κB

A series of hybrids (5a-r) of farnesylthiosalicylic acid (FTS) and hydroxylcinnamic acid were designed and synthesized. Most of the hybrids displayed potent antiproliferative activity against seven cancer cell lines in vitro, superior to FTS as well as sorafenib. The most potent compound 5f selectively inhibited cancer cells but not non-tumor liver cell proliferation in vitro, and significantly induced SMMC-7721 cell apoptosis. Interestingly, 5f could simultaneously inhibit not only Ras-related signaling but also phosphorylated NF-κB, which may synergetically contribute to the cell growth inhibition and apoptosis induction. Moreover, 5f showed low acute toxicity to mice and significantly inhibited the hepatoma tumor growth. the Partner Organisations 2014.

Design and synthesis of novel NO-donor-ferulic acid hybrids as potential antiatherosclerotic drug candidates a

Novel NO-donor-ferulic acid hybrids were designed and synthesized through a symbiotic approach using ferulic acid and three different NO-donating groups, such as nitric ester, 4-hydroxyl-3-phenylfuroxan, and 4-hydroxymethyl-3- phenylsulfonylfuroxan. Antioxidant, nitric oxide release, and vasodilator properties studies showed that the target phenylsulfonylfuroxan 14, especially 14c, while keeping the antioxidant activity, showed more NO release activity and vasodilating activity than isosorbide dinitrate (ISDN). Thus, 14c may be considered a novel potent anti-atherosclerosis drug candidate.

USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN

The present invention relates to nitrooxyderivative of antioxidant compounds of formula (I) and pharmaceutically acceptable salts or stereoisomers thereof for the treatment of chronic pain, in particular chronic neuropathic pain. The invention also descri

NITRATE ESTERS OF CARBONIC ANHYDRASE INHIBITORS

Nitroderivatives of carbonic anhydrase inhibitors having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies, cancer, epilepsy, high-altitude disorders and neuromuscular diseases.

PROSTAGLANDIN NITROOXYDERIVATIVES

Prostaglandin nitrooxyderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Drugs for diabetes

Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0—(C)c0—NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking group wherein the precursor must meet the tests described in the application, C is a a bivalent linking group as defined in the invention.